HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $80.00 price target on the biopharmaceutical company's stock.
CLDX has been the topic of a number of other research reports. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a "neutral" rating and a $45.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a "buy" rating and a $70.00 target price for the company. Finally, Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $62.25.
View Our Latest Research Report on Celldex Therapeutics
Celldex Therapeutics Stock Up 5.7 %
Shares of Celldex Therapeutics stock traded up $1.42 during trading on Wednesday, reaching $26.40. 1,123,258 shares of the company were exchanged, compared to its average volume of 877,850. The business has a 50-day moving average price of $31.17 and a 200-day moving average price of $35.15. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -9.72 and a beta of 1.60. Celldex Therapeutics has a twelve month low of $22.93 and a twelve month high of $53.18.
Insider Buying and Selling
In other Celldex Therapeutics news, CEO Anthony S. Marucci purchased 11,500 shares of the company's stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Celldex Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC raised its holdings in shares of Celldex Therapeutics by 45.2% during the 1st quarter. ProShare Advisors LLC now owns 11,166 shares of the biopharmaceutical company's stock worth $469,000 after acquiring an additional 3,476 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company's stock worth $153,215,000 after buying an additional 604,251 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock worth $260,000 after acquiring an additional 1,582 shares in the last quarter. American International Group Inc. raised its holdings in shares of Celldex Therapeutics by 32.6% in the first quarter. American International Group Inc. now owns 30,629 shares of the biopharmaceutical company's stock worth $1,285,000 after buying an additional 7,535 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its position in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock worth $192,000 after acquiring an additional 955 shares during the period.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
